Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study

References

• Lund B, Kristjansen PE, Hansen HH. Clinical and preclinical activity of 2ʹ,2ʹ-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev. 1993;19(1):45–55.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet (London, England). 2016;388(10039):73–85. doi:10.1016/S0140-6736(16)00141-0
   PubMed Web of Science ®Google Scholar
• Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010;11(12):1142–1148. doi:10.1016/S1470-2045(10)70247-321071270
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–222. doi:10.1016/S1470-2045(13)70604-124439929
   PubMed Web of Science ®Google Scholar
• Seddon B, Strauss SJ, Whelan J, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18(10):1397–1410. doi:10.1016/S1470-2045(17)30622-828882536
   PubMed Web of Science ®Google Scholar
• Naiki T, Iida K, Etani T, et al. Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis. Cancer Manag Res. 2018;10:3669–3677. doi:10.2147/CMAR.S17291330271215
   PubMed Web of Science ®Google Scholar
• Zhang J, Lin Y, Sun XJ, et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Ann Oncol. 2018;29(8):1741–1747. doi:10.1093/annonc/mdy20929905759
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Goldstein D, Korn RL, et al. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. Ann Oncol. 2016;27(4):648–653. doi:10.1093/annonc/mdw02026802153
   PubMed Web of Science ®Google Scholar
• Lee JK, Capanu M, O’Reilly EM, et al. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. Br J Cancer. 2013;109(4):915–919. doi:10.1038/bjc.2013.43223900219
   PubMed Web of Science ®Google Scholar
• Katakami N, Felip E, Spigel DR, et al. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung cancer. Ann Oncol. 2017;28(9):2241–2247. doi:10.1093/annonc/mdx28428911085
   PubMed Web of Science ®Google Scholar
• Baker JA, Wickremsinhe ER, Li CH, et al. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase. Drug Metab Dispos. 2013;41(3):541–545. doi:10.1124/dmd.112.04876923230131
   PubMed Web of Science ®Google Scholar
• Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science (New York, NY). 2017;357(6356):1156–1160. doi:10.1126/science.aah5043
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–216. doi:10.1093/jnci/92.3.20510655437
   PubMed Web of Science ®Google Scholar
• Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The clinical trial review committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 1993;23(4):250–257.8411739
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56–e93. doi:10.1093/cid/cir07321258094
   PubMed Web of Science ®Google Scholar
• Wallace BD, Wang H, Lane KT, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science (New York, NY). 2010;330(6005):831–835. doi:10.1126/science.1191175
   Google Scholar
• Li A, Yeo K, Welty D, Rong H. Development of guanfacine extended-release dosing strategies in children and adolescents with ADHD using a physiologically based pharmacokinetic model to predict drug-drug interactions with moderate CYP3A4 inhibitors or inducers. Paediatr Drugs. 2018;20(2):181–194. doi:10.1007/s40272-017-0270-029098603
   PubMed Web of Science ®Google Scholar
• Zhang L, Wei MJ, Zhao CY, Qi HM. Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes. Acta Pharmacol Sin. 2008;29(12):1507–1514. doi:10.1111/j.1745-7254.2008.00908.x19026171
   PubMed Web of Science ®Google Scholar
• Chattopadhyay N, Kanacher T, Casjens M, et al. CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans. Br J Clin Pharmacol. 2018. doi:10.1111/bcp.13750
   PubMed Web of Science ®Google Scholar
• Pan X, Li Y, Qiu Y, et al. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults. Clin Ther. 2010;32(12):2003–2011. doi:10.1016/j.clinthera.2010.11.00521118735
   PubMed Web of Science ®Google Scholar
• Paolini M, Poul L, Berjaud C, et al. Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel. Int J Nanomed. 2017;12:5537–5556. doi:10.2147/IJN.S141145
   PubMed Web of Science ®Google Scholar
• Parra-Guillen ZP, Berger PB, Haschke M, et al. Role of cytochrome P450 3A4 and 1A2 phenotyping in patients with advanced non-small-cell lung cancer receiving erlotinib treatment. Basic Clin Pharmacol Toxicol. 2017;121(4):309–315. doi:10.1111/bcpt.1280128444958
   PubMed Web of Science ®Google Scholar
• Chugh R, Wagner T, Griffith KA, et al. Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma. Cancer. 2007;109(11):2315–2322. doi:10.1002/cncr.2266917464949
   PubMed Web of Science ®Google Scholar
• Niwa T, Shiraga T, Hashimoto T, Kagayama A. Effect of cefixime and cefdinir, oral cephalosporins, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull. 2004;27(1):97–99. doi:10.1248/bpb.27.9714709907
   PubMed Web of Science ®Google Scholar
• Zhou BS, Tsai P, Ker R, et al. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis. 1998;16(1):43–49. doi:10.1023/A:10065599017719502076
   PubMed Web of Science ®Google Scholar
• Zhou J, Oliveira P, Li X, Chen Z, Bepler G. Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines. J Nucleic Acids. 2010;2010:597098. doi:10.4061/2010/59709820976259
   PubMedGoogle Scholar
• Chen M, Xue X, Wang F, et al. Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer. Oncol Rep. 2012;27(1):265–269. doi:10.3892/or.2011.147521956451
   PubMed Web of Science ®Google Scholar
• Guazzelli A, Meysami P, Bakker E, et al. BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment. Int J Mol Sci. 2019;20(2). doi:10.3390/ijms20020429
   PubMed Web of Science ®Google Scholar